New combo aims to save esophagus in advanced cancer patients
NCT ID NCT07622797
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining the immunotherapy drug camrelizumab with chemotherapy and radiation can shrink advanced esophageal cancer enough to avoid surgery. About 164 patients with stage II to IVa esophageal squamous cell carcinoma will receive one of two drug combinations plus radiation. If the cancer disappears completely, they continue on camrelizumab alone; if not, they proceed to surgery followed by camrelizumab. The goal is to see if this approach can preserve the esophagus while controlling the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
camrelizumab (an immunotherapy drug) combined with chemotherapy (albumin-bound paclitaxel, carboplatin, or capecitabine) and radiotherapy
What this could lead to
If successful, this approach could allow many patients with advanced esophageal cancer to avoid surgery and keep their esophagus, while still controlling the disease.
What could go wrong
This is a Phase 2 trial with only 164 participants, so results are preliminary. The combination may cause significant side effects, and not all patients will respond—some may still need surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LATE-STAGE RESECTABLE ESOPHAGEAL SQUAMOUS CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Henan University of Science and Technology
RECRUITINGLuoyang, Henan, 471000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••